星昊医药
(920017)
| 流通市值：22.44亿 | | | 总市值：22.68亿 |
| 流通股本：1.23亿 | | | 总股本：1.24亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 314,456,566.52 | 158,348,371.9 | 650,139,997.82 | 474,999,356.63 |
| 营业收入 | 314,456,566.52 | 158,348,371.9 | 650,139,997.82 | 474,999,356.63 |
| 二、营业总成本 | 268,138,160.67 | 130,347,236.65 | 542,987,849.51 | 393,132,024.11 |
| 营业成本 | 93,435,772.27 | 43,813,840.88 | 194,932,802.94 | 141,743,695.34 |
| 税金及附加 | 4,696,425.22 | 1,763,236.98 | 10,092,895.94 | 5,738,735.78 |
| 销售费用 | 116,035,516.63 | 54,985,922.13 | 223,924,756.12 | 159,498,437.59 |
| 管理费用 | 19,245,562.6 | 10,954,380.34 | 47,678,185.11 | 40,657,504.11 |
| 研发费用 | 36,980,761.08 | 19,942,828.69 | 75,475,769.96 | 52,823,441.16 |
| 财务费用 | -2,255,877.13 | -1,112,972.37 | -9,116,560.56 | -7,329,789.87 |
| 其中:利息费用 | 118,805.55 | 58,750 | 259,388.88 | 201,361.11 |
| 其中:利息收入 | 3,253,136.25 | 1,725,787.52 | 8,519,477.96 | 6,303,234.66 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 3,481,390.42 | 1,613,986.31 | 3,538,306.82 | 2,110,425.27 |
| 加:投资收益 | 1,819,917.16 | 869,620.99 | 3,802,693.03 | 2,913,745.47 |
| 资产处置收益 | - | - | -36.47 | -36.47 |
| 资产减值损失(新) | -2,728,950.96 | -178,002.33 | -6,368,590.38 | -3,359,273.23 |
| 信用减值损失(新) | 572,730.29 | 164,100.13 | -11,937,839.42 | -2,386,106.46 |
| 其他收益 | 10,398,189.24 | 5,690,921.99 | 21,234,860.52 | 15,398,411.25 |
| 四、营业利润 | 59,861,682 | 36,161,762.34 | 117,421,542.41 | 96,544,498.35 |
| 加:营业外收入 | 309,358.95 | 0 | 1,008,397 | 389,666.34 |
| 减:营业外支出 | 2,041,945.25 | 50,000 | 492,746.5 | 404,398.19 |
| 五、利润总额 | 58,129,095.7 | 36,111,762.34 | 117,937,192.91 | 96,529,766.5 |
| 减:所得税费用 | 4,889,021.61 | 4,322,820.27 | 14,892,393.8 | 10,276,807.81 |
| 六、净利润 | 53,240,074.09 | 31,788,942.07 | 103,044,799.11 | 86,252,958.69 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 53,240,074.09 | 31,788,942.07 | 103,044,799.11 | 86,252,958.69 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 53,240,074.09 | 31,788,942.07 | 103,044,799.11 | 86,252,958.69 |
| 扣除非经常损益后的净利润 | 49,386,925.03 | 28,878,516.25 | 93,832,768.2 | 75,278,307.92 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.43 | 0.25 | 0.84 | 0.7 |
| (二)稀释每股收益 | 0.43 | 0.25 | 0.84 | 0.7 |
| 八、其他综合收益 | -723,739.64 | -1,172.31 | -3,828,310.05 | -4,257,248.91 |
| 归属于母公司股东的其他综合收益 | -723,739.64 | -1,172.31 | -3,828,310.05 | -4,257,248.91 |
| 九、综合收益总额 | 52,516,334.45 | 31,787,769.76 | 99,216,489.06 | 81,995,709.78 |
| 归属于母公司股东的综合收益总额 | 52,516,334.45 | 31,787,769.76 | 99,216,489.06 | 81,995,709.78 |
| 归属于少数股东的综合收益总额 | 0 | - | 0 | - |
| 公告日期 | 2026-08-10 | 2026-04-29 | 2026-04-24 | 2025-10-28 |
| 审计意见(境内) | | | 标准无保留意见 | |